SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is trending due to a series of news announcements, including new smart power components leveraging GaN technology and advancements in silicon photonics for AI data centers. The community is also discussing the company's AI solutions for industrial, consumer, and automotive applications. Some investors are concerned about the share price decline despite the bullish news, while others highlight the share repurchase program and potential for a short squeeze.

shark raptor rocket launcher

SRRL is trending as traders discuss its price action, pointing to steady momentum and clean structure. The community highlights the potential for a significant move, watching for signs of increasing volume and sustained trendline support. Conversations also mention where to buy SRRL, indicating increased interest in the cryptocurrency.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as the community discusses its potential to lead in AI, particularly after positive reviews for its Gemini 3 model and news that Meta may use Google's TPUs. Some are speculating about the implications for competitors like NVDA and OpenAI, while others point to GOOGL's attractive valuation relative to its growth potential and peers.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr Inc. is trending due to the board halting buyout discussions over financing concerns regarding the $18/share take-private bid from major shareholders, leading to community speculation about a potential hostile takeover and the motives of involved parties. Discussions include insider selling activity and the possibility of other potential buyers emerging, as well as the company's intrinsic value.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as discussions around its AI capabilities intensify, particularly with comparisons to competitors like NVDA and MSFT. The community is debating whether GOOG is winning the AI race, highlighting its TPU technology and potential market share gains. Additionally, analyst commentary and price target updates are contributing to the increased interest in the stock.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets (SSB) is trending with community members highlighting its disciplined chart structure, calm price flow, and balanced candles. Traders are closely watching for signs of accumulation and potential breakouts, emphasizing the importance of patience and composure in trading SSB. There's also discussion around a Litecoin migration in the future.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending as community members discuss its potential, future price predictions, and accumulation strategies. Some are pointing to the underlying technology and upcoming smart contracts as reasons for optimism, while others express frustration with the price action. Speculation around potential exchange listings on platforms like Coinbase and Binance is also fueling conversation.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending amid optimism in the lithium sector, driven by forecasts of a supply deficit in 2026 and rising lithium prices, sparking community discussion about potential short squeezes and target prices. Despite positive sentiment, some traders point out potential risks such as insider selling, missing construction approvals, and China's influence on lithium prices. Overall, the community is weighing the potential for significant gains against concerns of overvaluation and market manipulation.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy ($LEU) is trending due to renewed interest in nuclear energy and its unique position as the only U.S. company licensed to produce High-Assay, Low-Enriched Uranium (HALEU). Community discussions revolve around the stock's potential amidst government support for nuclear power and its role in powering AI infrastructure, with some cautioning about valuation. Options trading and short squeeze speculation are also contributing to the heightened interest.

Next Technology Holding, Inc. engages in the provision of software development services to the customers and bitcoin acquisition. The company was founded on March 28, 2019 and is headquartered in Shenzhen, China.

Next Technology Holding Inc.

NXTT is trending as investors discuss the potential impact of a reverse stock split and recent dilution on the company's value, particularly in relation to its Bitcoin holdings. Community sentiment is mixed, with some expressing disappointment and frustration while others remain optimistic about a potential rebound linked to crypto market movements. Concerns about management decisions and the company's overall direction are also prevalent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Stock Reports for Alphabet, Roche & RTX

Alphabet gains momentum as AI-driven growth in Cloud, Search and YouTube fuels rising customer adoption and revenue strength.

REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD

Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion. 



RHHBY Reports Positive Phase III Data on Breast Cancer Drug 

Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.

<ul class="summary-bullets"><li>Olema’s lead product candidate, Palazestrant, belongs to the same class of drugs as Roche’s and is being studied in breast cancer.&nbsp;</li><li>Oppenheimer raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.&nbsp;</li><li>The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.</li></ul>Shares of Olema Pharmaceuticals Inc. (OLMA) more than doubled Tuesday morning on the heels of Roche announcing positive results from its late-stage trial in breast cancer.Roche was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.roche.com/media/releases/med-cor-2025-11-18">evaluating</a> Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. In the study, Giredestrant treatment showed a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard-of-care endocrine therapy.Giredestrant is an investigational, oral, selective oestrogen receptor degrader or SERD. According to Roche, this is the first late-stage study of a SERD to demonstrate a significant benefit in the adjuvant setting.<h2 class="st-heading-2">Expert Take</h2>As per Oppenheimer, Olema shares were trading pre-market on news that Roche's (RHHBY) trial met its primary endpoint. The analyst subsequently raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.Oppenheimer said it was not expecting this readout, as the entire narrative has been around Roche's different breast cancer clinical trials. Nonetheless, the data are a welcome surprise, it added.Early breast cancer is a multi-billion-dollar market, and one that the firm did not have in its model. These data also incrementally derisk another Roche drug trial, which is testing oral SERDS against aromatase inhibitors in the frontline metastatic setting, Oppenheimer added.Olema’s lead product candidate, Palazestrant, is also a SERD being investigated in patients with recurrent, locally advanced, or metastatic forms of breast cancer. It is being evaluated as a single agent in a late-stage trial and in combination with ribociclib in another late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OLMA">OLMA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/59;" src="data:image/png;base64,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" width="622" height="59" alt="OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed pessimism about the stock, noting that the hype had passed by pre-market hours, when the stock was up over 200%.<stembedurl>https://stocktwits.com/ChannelRed/message/636586904</stembedurl>Another user, however, believes the stock will touch $100.<stembedurl>https://stocktwits.com/murphylaw/message/636586451</stembedurl>OLMA stock is up by 233% this year and by 125% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-shifts-to-royalty-driven-model-approves-125-m-buyback-plan/cLPVdKtRE7F">Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Equity

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.


Never Mind the Cloudflare System Issues, Here’s the Morning Market Update

DENVER, Colo., Nov 18, 2025 (247marketnews.com)- Roche Group’s (OTCQX:RHHBY) Genentech, reported positive Phase III results...
The post Never Mind the Cloudflare System Issues, Here’s the Morning Market Update appeared first on 24/7 MarketNews.

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.

Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus

Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.

EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales

Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.

Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down

CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues. Stock falls.

SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure

Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG - ADR

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

RHHBY
Roche Holdings AG ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RHHBY News

RHHBYRoche Holdings AG ADR